In July, the six viral marker assay conversion at CTS Dallas, Phoenix and Tampa laboratories was achieved with minimal disruption and substantial cost saving to our healthcare partners.
Transitioned all 5 CTS labs from an investigational new drug (IND) to a licensed pooled Babesia test...
CTS Tampa lab implemented the Ortho Clinical Diagnostics VITROS® testing platform to perform COVID-1...
In August CTS begins source plasma testing as a new line of business to one of the largest plasma fr...
By the end of 2017, CTS has secured three source plasma partners and continues to seek additional pa...
Continue to meet or exceed healthcare partners’ expectations by providing on-time test results appr...
CTS embraces a company-wide operational excellence initiative designed to change the culture to enha...